INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Option exerciseVerified data

Sachs David C. reported IBRX

Chief Financial Officer · ImmunityBio, Inc. · ImmunityBio, Inc. — Restricted Stock Units

Side
M
Value
—
Shares
82.2K
Price
—
Executed
Feb 10, 2026
Disclosed
Feb 12, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 10 executedFeb 12, 2026 disclosed

IBRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
21/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 100.0% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IBRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    20
    Lisa C. McClainRSpouse
    IBRXImmunityBio, Inc.
    Purchase
    		BUY$1,001 – $15KSep 30, 2026Oct 12, 2026
    traded Sep 30, 2026
    		+12dHOUSE PTR

    Evidence

    24
    Lisa C. McClainRSpouse
    IBRXImmunityBio, Inc.
    Purchase
    		BUY$1,001 – $15KSep 28, 2026Oct 12, 2026
    traded Sep 28, 2026
    		+14dHOUSE PTR

    Evidence

    8
    SJ
    Simon Barry J.Director
    IBRXImmunityBio, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$197K
    25.0K sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    5
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Grant or award
    		A—
    65.6K sh
    		Jun 9, 2026Jun 10, 2026
    traded Jun 9, 2026
    		+1dSEC FORM 4

    Evidence

    9
    ML
    Maxwell LindaDirector
    IBRXImmunityBio, Inc.
    Grant or award
    		A—
    65.6K sh
    		Jun 9, 2026Jun 10, 2026
    traded Jun 9, 2026
    		+1dSEC FORM 4

    Evidence

    19
    SC
    Sachs David C.Chief Financial Officer
    IBRXImmunityBio, Inc.
    Tax withholding
    		F$296K
    42.6K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    17
    SC
    Sachs David C.Chief Financial Officer
    IBRXImmunityBio, Inc.
    Option exercise
    		M—
    82.2K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    29
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$250K
    50.0K sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    16
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$188K
    25.0K sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    0
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Option exercise · 10b5-1 plan
    		M$75K
    25.0K sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    3
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Option exercise · 10b5-1 plan
    		M—
    25.0K sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    17
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Option exercise · 10b5-1 plan
    		M—
    50.0K sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    8
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Option exercise · 10b5-1 plan
    		M$149K
    50.0K sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001848899-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 10, 2026
    Published
    Feb 12, 2026
    Ingested by INSIDER
    Nov 5, 04:17 UTC
    Last re-read
    Nov 5, 04:17 UTC

    Extracted facts

    Filer
    Sachs David C.
    Role
    Chief Financial Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    ImmunityBio, Inc. — Restricted Stock Units
    Ticker
    IBRX
    Shares
    82.2K
    Price per share
    $0
    Execution date (reported)
    Feb 10, 2026
    Owned after transaction
    164.5K shares
    Days from execution to publication
    2

    What this establishes

    Sachs David C. filed this Form 4 reporting a option exercise of IBRX on Feb 10, 2026. It became public on Feb 12, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Sachs David C.cik:0001848899
    Issuer
    ImmunityBio, Inc.cik:0001326110

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.